🇺🇸 FDA
Pipeline program

CT0590 CAR T Cells

CT0590-CG6012

Unknown mab active

Quick answer

CT0590 CAR T Cells for Relapsed and/or Refractory Multiple Myeloma is a Unknown program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Relapsed and/or Refractory Multiple Myeloma
Phase
Unknown
Modality
mab
Status
active

Clinical trials